CSIMarket
 
Chinook Therapeutics Inc   (KDNY)
Other Ticker:  
 
 
Price: $40.3900 $0.09 0.223%
Day's High: $40.51 Week Perf: 0.27 %
Day's Low: $ 40.30 30 Day Perf: 3.27 %
Volume (M): 4,925 52 Wk High: $ 40.51
Volume (M$): $ 198,917 52 Wk Avg: $29.74
Open: $40.31 52 Wk Low: $18.34



 Market Capitalization (Millions $) 2,892
 Shares Outstanding (Millions) 72
 Employees -
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -246
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 3

Chinook Therapeutics Inc
Chinook Therapeutics Inc is a biotechnology company that specializes in developing precision medicines for kidney diseases. The company focuses on delivering targeted therapies to patients with rare and severe forms of kidney disorders. Chinook Therapeutics aims to discover and develop innovative treatments that can change the trajectory of kidney disease and improve patients' lives. Through their rigorous research and development efforts, they strive to address the unmet medical needs in the field of nephrology and make a significant impact on patients' health outcomes.


   Company Address: 400 Fairview Avenue North, Suite 900 Seattle 98109 WA
   Company Phone Number: 485-7241   Stock Exchange / Ticker: NASDAQ KDNY
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Chinook Therapeutics Inc

Dazzling Revenue Leap for Chinook Therapeutics Inc. Still Falls Short of Turning Profit in Q2 2023


Introduction
Chinook Therapeutics Inc, a leading biotechnology company, recently announced a remarkable increase in revenue of 141.148% year on year to $1.01 million in their most recent fiscal period. Despite this positive development, the company experienced an increase in per-share deficit and a substantial decline in revenue compared to the previous reporting season. In the second quarter of 2023, Chinook Therapeutics Inc recorded a net deficit of $-66.944 million, a significant increase from the previous year. While the company faces certain challenges, there are some promising signs as well.
Revenue Growth and Deficit Increase
Chinook Therapeutics Inc showed an impressive revenue growth of 141.148% year on year, reaching $1.01 million. This surge in revenue suggests that the company is successfully expanding its customer base and generating higher sales. It is a significant achievement worthy of attention within the stock market.
However, the company's per-share deficit worsened in the most recent fiscal period. In comparison to the previous reporting season, the deficit per share increased from $-0.85 to $-0.94. This increase in deficit raises concerns about the company's ability to efficiently manage costs and achieve profitability. Investors may need to closely monitor how Chinook Therapeutics Inc addresses this issue in future financial reports.






 

Chinook Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com